




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

5/25




Figure 7




Figure 8




Figure 9




Figure 10

8/25






Figure 11

9/25



(A)



(B)

Figure 12

10/25




Figure 13




Figure 14

11/25




Figure 15

12/25

Viability of NIT-1 Cells at Glucose 5.5 mM




Figure 16

Viability of NIT-1 Cells at Glucose 25.5 mM




Figure 17

13/25

Passive avoidance test
14 weeks




Figure 18

Novel Object Recognition test




Figure 19




Figure 20




Figure 21




Figure 22




Figure 23




Figure 23 (continued)




Figure 24




Figure 25

19/25




Figure 25 (continued)




Figure 26

21/25




Figure 27




Figure 28




Figure 28 (continued)




Figure 29

24/25





Figure 30



B=Blank (only treated with 2nd Ab Alexa Fluor® 647; C1= Control without any treatment ; C2=Control (treatment with 12.5mM AAPH)

Figure 31




Figure 32